InflaRx (IFRX) announced that the World Health Organization has granted the international nonproprietary, or generic, name of “izicopan” to the company for its orally available C5aR inhibitor, formerly known as INF904, in accordance with the WHO’s Procedure for the Selection of Recommended International Nonproprietary Names for Pharmaceutical Substances. In the next step of this process, the name “izicopan” will be published in the recommended list of INNs.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IFRX:
- InflaRx downgraded to Market Perform from Outperform at Leerink
- Largest borrow rate increases among liquid names
- Cautious Hold Rating for InflaRx’s INF904 Amid Uncertainties in Trial Results
- InflaRx price target raised to $8 from $3 at Cantor Fitzgerald
- InflaRx price target raised to $9 from $2 at Raymond James